FLT3 in lineage specification and plasticity

Sarah Greenblatt; Donald Small

doi:10.18632/oncotarget.499

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

FLT3 in lineage specification and plasticity

Sarah Greenblatt and Donald Small _

PDF | HTML | How to cite

Oncotarget. 2012; 3:576-580. https://doi.org/10.18632/oncotarget.499

Metrics: PDF 2246 views | HTML 2758 views | ?

Abstract

Sarah Greenblatt1 and Donald Small1,2

1 Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD

2 Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD

Correspondence:

Donald Small, email:

Keywords: FLT3, B220, leukemia, lineage, differentiation

Received: May 14, 2012, Accepted: May 26, 2012, Published: May 27, 2012

Abstract

FLT3 is a receptor tyrosine kinase that is expressed in CD34+ hematopoietic stem/progenitor cells (HSPCs) and is important for both normal myeloid and lymphoid differentiation. FLT3 expression in Pax5 negative lymphoid precursors coincides with a window of multilineage differentiation potential in mice and humans. Recent work has shown that FLT3 activating mutations can collaborate with a Nup98-HoxD13 mutation to induce an aggressive acute leukemia. The leukemic initiating population in this model displayed properties of both lymphoid and myeloid precursors, making it a useful tool to study the role of FLT3 in lineage plasticity. Through a variety of assays, the leukemic initiating population was shown to be restricted to myeloid differentiation, suggesting that the B-lineage properties in these cells are due to the priming of lymphoid transcription programs in multipotent progenitors rather than a true capacity for B-cell maturation. The development of an undifferentiated myeloid leukemia in this model, also has implications for the role of FLT3 in the inhibition of myeloid differentiation. Here we discuss the insights gained from this model.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 499

Publication Alerts

Research Perspectives:

FLT3 in lineage specification and plasticity

Abstract